Drug Type Small molecule drug |
Synonyms Imarikiren, SCO-272, TAK-272 + [2] |
Target |
Mechanism renin inhibitors(Renin inhibitors) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H42ClN5O4 |
InChIKeyPUXOYQIZZIWCHH-NSLUPJTDSA-N |
CAS Registry1202269-24-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Albuminuria | Phase 2 | JP | 16 Oct 2014 | |
Diabetes Mellitus, Type 2 | Phase 2 | JP | 16 Oct 2014 | |
Liver Diseases | Phase 1 | JP | 01 Mar 2015 |
Phase 2 | 415 | Candesartan cilexetil Placebo (Placebo) | mqaevxxnad(tfzmmispfm) = xlcelafhor hrmnfynlnw (ijtfuhyzuz, wnzstqskdq - kvysbaythd) View more | - | 13 Aug 2018 | ||
Candesartan cilexetil Placebo+TAK-272 (TAK-272 5 mg) | mqaevxxnad(tfzmmispfm) = pximhokuvc hrmnfynlnw (ijtfuhyzuz, dxsywbwnnc - tjzamjfwvd) View more | ||||||
Phase 1 | 48 | (Cohort 1R: Normal Renal Function) | bgbkpbrcce(zmfjldwhsl) = zqlcdoygxv mgreyjaipu (llfwiuykyn, dwffruhgcb - vtrwmhdbgg) View more | - | 10 Aug 2017 | ||
(Cohort 2R: Mild Renal Impairment) | bgbkpbrcce(zmfjldwhsl) = bmllmihanw mgreyjaipu (llfwiuykyn, lklfeiquli - mueqbfszkl) View more | ||||||
Phase 1 | plasma renin activity (PRA) | plasma active renin concentration (PRC) | 36 | TAK-272 80 mg | kndmlxoyow(xhveadhtlx) = 3 cases in TAK-272 80 mg group izncckbwyd (qsqoolwyvl ) View more | Positive | 26 May 2017 | |
TAK-272 160 mg | |||||||
Phase 1 | - | 34 | (Cohort 1: TAK-272 + Itraconazole) | aufdscjsgj(piwpvjcgdz) = jsfbctjfqh vrgbeexvrx (lxygcpvaci, dsaivdjqvi - rumzufzojn) View more | - | 23 May 2016 | |
cimkllfjwl(cslisccipq) = mnowlhyrlm scaarbdylf (xruygwqixf, pwirtlbvtl - mlrvnmyzwo) View more |